Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.60 USD
Change Today -0.04 / -0.52%
Volume 2.7K
IMMY On Other Exchanges
As of 11:02 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

imprimis pharmaceuticals inc (IMMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/24/14 - $9.24
52 Week Low
10/13/14 - $6.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

imprimis pharmaceuticals inc (IMMY) Related Businessweek News

No Related Businessweek News Found

imprimis pharmaceuticals inc (IMMY) Details

Imprimis Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing proprietary compounded drug therapies to physicians and patients in the United States. The company owns, markets, and sells a portfolio of proprietary combination formulations in ophthalmology and urology. Its ophthalmic formulations include anti-inflammatory and anti-bacterial combination formulations, such as Tri-Moxi, a compounded formulation that is a combination of triamcinolone acetonide and moxifloxacin hydrochloride used as an injection during ocular surgery, as well as an eye drop in pre-and post-ocular surgery; and Tri-Moxi-Vanc, a compounded formulation, which is a combination of triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin used as an injection during ocular surgery. The company’s ophthalmic formulations also comprise Pred-Moxi, a compounded formulation that is a combination of prednisolone and moxifloxacin hydrochloride used as an eye drop in pre-and post-ocular surgery. Imprimis Pharmaceuticals, Inc. markets its ophthalmic formulations under the Dropless Therapy and LessDrops brands. It also offers urology formulations, including heparin and alkalinized lidocaine, a patented urologic formulation, which is delivered directly to the bladder for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of certain fibrotic conditions, including Peyronie’s disease. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

56 Employees
Last Reported Date: 03/12/15
Founded in 1998

imprimis pharmaceuticals inc (IMMY) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $327.5K
Chief Financial Officer
Total Annual Compensation: $154.1K
Compensation as of Fiscal Year 2014.

imprimis pharmaceuticals inc (IMMY) Key Developments

Imprimis Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Year Ending December 31, 2015

Imprimis Pharmaceuticals, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total revenues were $2.0 million, representing a 195% increase over revenues of $0.7 million recorded for the same period of 2014. Adjusted EBITDA loss was $2.6 million, or approximately $0.28 per share of common stock, for the second quarter compared to $1.9 million, or approximately $0.21 per share of common stock, for the same period a year ago. Net loss was $3.7 million or $0.39 per share compared with $2.6 million or $0.28 per share a year ago. For the six months, the company's total revenues were $3.5 million compared with $6.7 million a year ago. Net loss was $6.8 million or $0.72 per share compared with $4.9 million or $0.54 per share a year ago. For the year ending December 31, 2015, the company expects total revenue of $12.0 million to $13.5 million.

Imprimis Pharmaceuticals, Inc. Signs License Agreement to Bring Proprietary Compounded Ophthalmic Formulations to Ophthalmologists in Canada

Imprimis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand the company's proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.  Marketing permissions under the successful existing educational campaign brands developed by Imprimis, Go Dropless™ and LessDrops™, are also part of the agreement. The license agreement includes an initial cash license fee, and a per-unit royalty of the greater of $50, or 20% of the gross purchase price paid to Advanced Dosage.  The non-exclusive agreement requires certain diligence requirements on the part of Advanced Dosage and provides for the conversion of the license to an exclusive license on or before December 31, 2015, based upon the achievement of certain terms and conditions.

Imprimis Pharmaceuticals Expands Distribution of Its Proprietary Ophthalmic and Urologic Formulations into Texas and Virginia

Imprimis Pharmaceuticals, Inc. has expanded the availability of its proprietary ophthalmic and urologic compounded formulations to physicians and patients in Texas. The Company's expansion into the Lone Star State resulted from its recent acquisition of JT Pharmacy, Inc., d/b/a Central Allen Pharmacy, a compounding pharmacy located outside of Dallas. Imprimis' New Jersey compounding pharmacy also received licenses to dispense in Texas and Virginia.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMY:US $7.60 USD -0.04

IMMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMY.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMMY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.1x
Price/Book 13.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPRIMIS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at